Phase
Startup
rAAVen Therapeutics
rAAVen Therapeutics wants to help pave the way for the next generation of gene therapies. The company uses cloning, virus variant production and sequencing to build novel viral vectors for precision targeting of defined cell populations or with desired properties.
Prior to founding rAAVen Therapeutics, Marcus spent the last decade on DNA barcoding and AAV engineering. Marcus started his work at Lund University, where he developed novel DNA barcoding methods for AAV engineering and gene therapy. Beside this, he has also worked extensively on generating DNA libraries, how to sequence DNA libraries and enhancer-promoter optimization.
He holds a PhD in Neuroscience from Lund University and has postdoc experience from Michigan State University in Grand Rapids, MI and Barrow Neurological Institute in Phoenix, AZ. Marcus is also a co-founder of BRAVE Bioscience.
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
Cell factories for dairy processing
Automated microscopy image acquisition and analysis
Implants of magnesium alloys
Digital service for patients
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Effective treatments for brain tumors
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy
